利奈唑胺血浆浓度升高与耐多药结核治疗中严重毒性反应发生的关联
该回顾性队列纳入2011至2017年间因耐多药结核开始利奈唑胺治疗的连续患者146例,评估谷浓度与严重线粒体毒性(SMT)的关联。SMT发生57例(39%),发病率为0.38/人年(95%CI 0.30-0.49)。平均谷浓度>2 mg/L者SMT调整HR为2.35(95%CI 1.26-4.38;P=0.01),首次检出谷浓度>2 mg/L后SMT的HR为2.63(95%CI 1.55-4.47;P<0.01)。作者结论认为谷浓度>2 mg/L与严重毒性强烈相关,需个体化风险获益评估。
要点
- 146例耐多药结核患者中57例(39%)发生严重线粒体毒性,发病率0.38/人年(95%CI 0.30-0.49)。
- 平均谷浓度>2 mg/L者SMT调整HR为2.35(95%CI 1.26-4.38;P=0.01)。
- 首次检出谷浓度>2 mg/L后SMT的HR为2.63(95%CI 1.55-4.47;P<0.01)。
核心结论
- 利奈唑胺谷浓度>2 mg/L与耐多药结核治疗中严重治疗 emergent 毒性发生强烈相关。
- 在获得进一步前瞻性证据前,任何谷浓度>2 mg/L的患者均需对继续利奈唑胺治疗进行个体化风险获益评估。
研究设计与样本
- 回顾性评估2011至2017年间连续开始利奈唑胺治疗耐多药结核的患者,共纳入146例。
- 主要结局为利奈唑胺所致严重线粒体毒性(SMT),定义为导致停药的非神经毒性或骨髓毒性。
- 采用多变量Cox比例风险模型(含时变协变量)评估血浆利奈唑胺谷浓度>2 mg/L的影响。
主要发现
- 146例中57例(39%)发生SMT,发病率0.38/人年(95%CI 0.30-0.49)。
- 52例(35.6%)检出最高谷浓度>2 mg/L,22例(15%)平均谷浓度>2 mg/L。
- 平均谷浓度>2 mg/L者SMT调整HR为2.35(95%CI 1.26-4.38;P=0.01)。
- 首次检出谷浓度>2 mg/L后SMT的HR为2.63(95%CI 1.55-4.47;P<0.01)。
- 探索性分析中,较高最高谷浓度与毒性呈剂量依赖性关联,降低升高的谷浓度未恢复基线风险。
关键数值与推荐
- SMT定义为利奈唑胺所致神经毒性或骨髓毒性导致停药。
- 谷浓度阈值>2 mg/L用于评估与SMT的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. METHODS: We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates. RESULTS: SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk. CONCLUSIONS: Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.
引用
- Eimer J, Fréchet-Jachym M, Le Dû D, et al. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment. Clin Infect Dis. 2023. PMID: 35717636. doi:10.1093/cid/ciac485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。